Treatment of primary intraocular lymphoma with radiation therapy: a multi-institutional survey in Japan.
This study evaluated the clinical features and treatment outcome of 15 patients with primary intraocular lymphoma. There were nine females, with a median age of 68 years. Thirteen patients presented with bilateral lesions and median time from the onset of symptoms to diagnosis was 12 months. All but one showed the B-cell phenotype. All patients received radiation therapy (RT) with a median of 41 Gy and 10 were administered chemotherapy as well. Three patients were treated with high-dose methotrexate and nine received prophylactic cranial irradiation (PCI) with a median of 30.6 Gy. Thirteen patients obtained a complete remission. The 2-year overall and disease free survival were 74% and 58%, respectively. Although only one patient experienced local recurrence, PCI did not prevent intracranial recurrence. One patient developed a grade 3 cognitive disturbance. It was concluded that ocular RT was effective to control primary lesions. However, some modifications are indispensable to improve outcomes.
Isobe
Koichi
K
Japanese Society for Therapeutic Radiology and Oncology Study Group, and Department of Radiology, Chiba University Hospital, 1-8-01 Inohana, Chuo-ku, Chiba 260-8677, Japan. isobeko@ho.chiba-u.ac.jp
Ejima
Yasuo
Y
Tokumaru
Sunao
S
Shikama
Naoto
N
Suzuki
Gen
G
Takemoto
Mitsuhiro
M
Tsuchida
Emiko
E
Nomura
Miwako
M
Shibamoto
Yuta
Y
Hayabuchi
Naofumi
N
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005134:Eye Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy*; D005260:Female; D006306:Health Surveys; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008223:Lymphoma / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate